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Abstract
Since the 1980 s, when cell transplantation into the brain as a cure for Parkinson’s disease hit the headlines, several
patients with Parkinson’s disease have received transplantation of cells from aborted fetuses with the aim of repla-
cing the dopamine cells destroyed by the disease. The results in human studies were unpredictable and raised
controversy. Some patients showed remarkable improvement, but many of the patients who underwent transplan-
tation experienced serious disabling adverse reactions, putting an end to human trials since the late 1990 s. These
side effects consisted of patients’ developing troublesome involuntary, uncontrolled movements in the absence of
dopaminergic medication, so-called off-phase, graft-induced dyskinesias. Notwithstanding the several mechanisms
having been proposed, the pathogenesis of this type of dyskinesias remained unclear and there was no effective
treatment. It has been suggested that graft-induced dyskinesias could be related to fiber outgrowth from the graft
causing increased dopamine release, that could be related to the failure of grafts to restore a precise distribution of
dopaminergic synaptic contacts on host neurons or may also be induced by inflammatory and immune responses
around the graft. A recent study, however, hypothesized that an important factor for the development of graft-
induced dyskinesias could include the composition of the cell suspension and specifically that a high proportion of
serotonergic neurons cografted in these transplants engage in nonphysiological properties such as false transmitter
release. The findings from this study showed serotonergic hyperinnervation in the grafted striatum of two patients
with Parkinson’s disease who exhibited major motor recovery after transplantation with fetal mesencephalic tissue
but later developed graft-induced dyskinesias. Moreover, the dyskinesias were significantly attenuated by adminis-
tration of a serotonin agonist, which activates the inhibitory serotonin autoreceptors and attenuates transmitter
release from serotonergic neurons, indicating that graft-induced dyskinesias were caused by the dense serotoner-
gic innervation engaging in false transmitter release. Here the implications of the recent findings for the develop-
ment of new human trials testing the safety and efficacy of cell transplantation in patients with Parkinson’s disease
are discussed.
Introduction
Parkinson’s disease (PD) is a common chronic neurode-
generative disorder characterized by the clinical presen-
tation of motor (tremor, rigidity and bradykinesia) and
nonmotor (e.g., autonomic, mood and cognitive) symp-
toms. Although the aetiology and pathogenetic mechan-
isms that cause PD remain unknown, classical
descriptions of PD pathology mainly focus on the
progressive degeneration of the nigrostriatal dopamine
(DA) pathway and the pathology in other brainstem,
cortical and subcortical structures [1]. PD patients are
given DA replacement therapy for symptomatic relief,
but these drugs prove beneficial up to a point and after
a few years of L-3,4-dihydroxyphenylalanine (L-DOPA)
therapy, the majority of PD patients develop motor
complications, including abnormal involuntary move-
ments called L-DOPA-induced dyskinesias (LIDs) [2].
As a result of this progressive decline in the clinical
course of PD, more sophisticated therapeutic manage-
ment has been warranted, one of which involves trans-
plantation of fetal ventral mesencephalic (VM) tissue in
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any medium, provided the original work is properly cited.the striatum of patients with PD. Human trials with fetal
VM transplantation for PD have been conducted over
the past two decades on the basis of the hypothesis that
if PD is caused by degeneration of the nigrostriatal DA
pathway and loss of DA innervation in the striatum,
then restoration of the lost DA neurons by transplanta-
tion could reverse the loss of motor function. However,
open-label trials and double-blind sham surgery
controlled trials yielded inconsistent results and raised
controversy [3]. Although some of the PD patients who
underwent transplantation showed remarkable improve-
ment of their motor symptoms, many of them had
severe adverse reactions consisting of developing trou-
blesome involuntary movements when off their DA
drugs, called off-phase, graft-induced dyskinesias (GIDs)
[4-6]. Whilst the exact mechanisms underlying the
development of GIDs have remained unknown and
there has been no effective treatment, proposed theories
have been subject to extensive debate.
Discussion
GIDs have been suggested to develop as a result of fiber
outgrowth from the graft, causing increased DA release
[4], or as the result of unevenly low or intermediate DA
release from the striatum due to the imbalanced DA
reinnervation [7]. However, two other studies argued
against this view and reported no differences in either
regional or global levels of striatal DA reinnervation
between PD patients who have undergone transplanta-
tion with and without GIDs [6] and no correlation
between GIDs and excessive DA reinnervation [5].
Other theories have included observations from ani-
mal models of PD and suggested that failure of the
grafts to restore DA synaptic contacts with the host
striatal neurons could result in abnormal signaling and
abnormal synaptic plasticity in the transplanted striatum
and therefore dyskinesia [8]. Furthermore, the occur-
rence of GIDs could be a result of inflammatory and
immune responses around the graft. Clinical observa-
tions have suggested that GIDs develop after early dis-
continuation of immunosuppressive therapy [6,9], with
signs of an inflammatory reaction around the grafts in
autopsied cases [6]. An immunological reaction around
the graft may cause a degree of tissue rejection, thereby
diminishing the restoration of sustained striatal synaptic
DA levels, which can be related to GIDs. Although both
of these hypotheses appear plausible, they require
experimental verification with animal and human
studies.
Recent work from our lab [10] has focused on another
population of neurons, namely, the serotonin (5-HT)
neurons that appear in developmental stages caudally to
the VM and were also transplanted. The hypothesis was
based on the ability of 5-HT neurons to convert, store
and release DA, as was shown after L-DOPA adminis-
t r a t i o ni na n i m a lm o d e l so fP D[ 1 1 ] .G a i no ff u n c t i o n
from a graft-derived, dense 5-HT terminal network in
an otherwise restored striatal DA neuron function
would lead to mishandling of the extracellular levels of
striatal DA from the 5-HT neurons and would be
responsible for the occurrence of GIDs.
Two patients with PD showing remarkable improve-
ment of their motor symptoms more than a decade
after striatal transplantation with fetal VM tissue, who
received no DA drugs but developed disabling GIDs,
were studied clinically and with positron emission tomo-
graphy (PET) and radioligands tagging markers of presy-
naptic DA and 5-HT neurons. The results indicated
excessive striatal 5-HT innervation in all grafted sites.
Systemic administration of a 5-HT1A agonist, buspirone,
which activates the inhibitory 5-HT autoreceptors and
attenuates transmitter release from serotonergic neu-
rons, resulted in significant attenuation of GIDs [10].
The results suggested that the occurrence of GIDs
in these patients is caused by a ‘dialog’ between the
graft-derived excess of 5-HT neurons and the normally
functioning DA neurons (Figure 1). The hypothesis
regarding this mechanism proposes that 5-HT neurons
are responsible for dysregulating the DA release in the
synapse. This could occur as a result of 5-HT transpor-
ters’ taking up DA and releasing it as a ‘false’ transmit-
ter from the 5-HT terminals and also as a result of the
excessive 5-HT release acting directly in DA neurons
a n di n d u c i n gf u r t h e rD Ar e l e a s eb yr e v e r s i n gt h eD A
transporters (DAT). Administration of a 5-HT1A agonist
(e.g., buspirone) interferes with this ‘dialog’ and by acti-
vating the inhibitory 5-HT autoreceptors attenuates the
transmitter release from the 5-HT neurons, thus leaving
m o s to ft h es y n a p t i cD At ob en o r m a l l yr e g u l a t e df r o m
the DA terminals. The clinical correspondence of such
interference is the significant attenuation of GIDs.
Animal models of PD have recently demonstrated that
removal of striatal 5-HT afferents or the dampening of
5-HT activity with 5-HT1A or 5-HT1B agonists resulted
in attenuation of LIDs [12]. However, whether LIDs and
GIDs share the exact same mechanism of DA dysregula-
tion from 5-HT neurons is unclear. Patients with PD
with peak-dose LIDs experience a radical and short-
term increase in striatal synaptic DA levels when exo-
genous L-DOPA reaches the extensively denervated
striatum [13]. In patients with PD who have restored
DA innervation from transplantation but steady and
constant presentation of GIDs, it seems plausible to
assume that the 5-HT-driven abnormal release of DA is
a phenomenon with prolonged and steady duration and
possibly of lower intensity compared to the one
observed in LIDs (Figure 2). This scenario is supported
by observations of GIDs responding to systemic
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Page 2 of 5Figure 1 Serotonin 1A (5-HT1A) agonists interfere with the ‘dialog’ between striatal dopamine (DA) and 5-HT neurons attenuating
graft-induced dyskinesias (GIDs). (a) In healthy individuals or in patients with Parkinson’s disease (PD) with successful striatal grafting and no
GIDs, there is no dialog between DA and 5-HT neurons. The release of DA (blue dots) is regulated by presynaptic dopamine transporters (DAT)
and the release of 5-HT (green dots) by serotonin transporters (SERT). (b) In patients with PD who have GIDs, the graft-derived striatal 5-HT
hyperinnervation causes dysregulation in the synaptic levels of DA that lead to dyskinesias. 5-HT neurons can take up DA via SERT and release it
as a false transmitter. Also, the excess of 5-HT release can act directly on DA neurons and reverse or alter the capacity of DAT, thus causing
greater DA release from the grafted DA terminals. (c) Administration of 5-HT1A agonists (red dots) in patients with PD who have GIDs activate
the inhibitory 5-HT autoreceptors, thereby diminishing the false release of DA and the excess release of 5-HT from the 5-HT terminals, leading to
restoration of striatal synaptic levels of DA and attenuation of dyskinesias.
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while LIDs responding to large bolus doses of the same
drug aim for a more complete block of the concentrated
5-HT neuronal release of neurotransmitters [14].
Conclusions
The occurrence of GIDs is a serious adverse reaction of
striatal transplantation with fetal VM tissue in patients
with PD hindering the development of future cell
replacement therapies. The 5-HT hypothesis underlying
the development of GIDs is the first hypothesis with
experimental verification [10]. These recent findings
have also supported a causative relationship between the
striatal 5-HT hyperinnervation and the intensity of
GIDs. According to these recent findings, GIDs could
be prevented or treated. Patients with PD in its early
stages lose about 15% and patients with advanced PD
lose about 30%-35% of putaminal 5-HT neurons [15]
Figure 2 Striatal DA release in peak-dose L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias (LIDs) and GIDs. (a) Physiological
release of DA in the striatum of healthy individuals. (b) Patients with PD who have peak-dose LIDs experience a sharp, short-term, abnormal
increase in striatal synaptic DA concentrations when large doses of L-DOPA are administered and reach the extensively denervated striatum.
Once the L-DOPA effect wears off, levels of DA drop below normal range. (c) Patients with PD who have striatal DA reinnervation rising to
normal levels following transplantation with fetal ventral mesencephalic (VM) tissue experience constant GIDs because of the excessive 5-HT
innervation in the grafted striatum. The 5-HT, neuron-derived, irregular levels in synaptic DA concentrations is a phenomenon with prolonged
and steady duration and possibly lower intensity compared to LIDs.
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GIDs may be prevented by minimizing the serotonergic
component in the grafted tissue during the dissection of
VM, which should be very low in patients in the early
stages of PD. Additionally, the use of fresh tissue should
be applied because storage and culturing is expected to
alter the proportion of cells in favor of non-DA cells
such as 5-HT. GIDs could also be treated by the admin-
istration of 5-HT1A agonists, but the benefit could be
greater and more practical by developing 5-HT1A ago-
nists with sustained release.
However, more data are needed to fully establish the
‘terms’ of 5-HT/DA neuron ‘dialog’. These data should
come from transplanted PD patients with different
degree of 5-HT/DA striatal reinnervation and should
include those with incomplete DA reinnervation and
those who do not experience GIDs.
The verification of the 5-HT hypothesis in the devel-
opment of GIDs alongside the intense animal and
human research of the past decade since the abandon-
ment of fetal cell therapy in PD, indicates that we have
come closer to designing new optimized protocols for
the safer and more effective application of fetal cell
transplantation in patients with PD.
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